
DOCKET NUMBER PETITION RULE PRM (SYFR 38239)



NOV 30 P5:03

Secretary of the Commission U.S. Nuclear Regulatory Commission Docketing and Service Branch, Docket # PRM-35-9 OFFICE CLASSICAL TARY Washington, D.C. 20555 November 27, 1989

BRANCH

We are writing to express our strong support for the Petition for Rulamaking filed by the American College of Nuclear Physicians and the Society of Nuclear Medicine. We are practicing nuclear pharmacists at Syncor International Corporation in Cincinnati, Ohio. We are deeply concerned over the revised 10 CFR 35 regulations (effective April, 1987) governing the medical use of byproduct material. They significantly impact our ability to practice high-quality Nuclear Pharmacy and are preventing us from providing optimized care to individualized patients.

For example, we are forced to strictly follow the manufacturer's instructions for kit preparation and expiration times.

The NRC should recognize that the FDA does allow, and often encourages other clinical uses of approved drugs, and actively discourages the submission of physician-sponsored IND's that descride new indications for approved drugs. The package insert was never intended to prohibit physicians from deviating from it for other indications; on the contrary, such deviation is necessary for growth in developing new diagnostic and therapoutic procedures. In many cases, manufacturers will never go back to the FDA to revise a package insert to include a new indication because it is not required by the FDA and there is simply no economic incentive to do so.

Currently, the regulatory provisions in Part 35 (35.100, 35.200, 35.300 and 33.17(a)(4)) do not allow practices which are legitimate and legal under FDA regulations and Ohio medicine and pharmacy laws. These regulations therefore inappropriately interfere with the practice of medicine, which directly contradicts the NRC's Medical Policy statement against such interference.

Finally, we would like to point out that highly restrictive NRC regulations will only jeopardize public health and safety by: restricting access to appropriate Nuclear Medicine procedures; exposing patients to higher radiation absorbed doses from alternative legal, but non-optimal studies; and exposing hospital personnel to higher radiation absorbed doses because of unwarrented, repetitive procedures. The NRC should not strive to construct proscriptive regulations to cover all aspects of medicine, nor should it attempt to regulate radiopharmaceutical use. Instead, the NRC should rely on the expertise of the FDA, State Boards of Pharmacy, State Boards of Medical Quality Assurance, the Joint Commission of Accreditation of Healthcare Organizations, radiation safety committees, institutional Q/A review procedures, and most importantly, the professional judgement of physicians and pharmacists who have been well-trained to administer and 8912050208 891127 PDR PRM 35-9 prepare these materials.

Innovators in high-tech pharmacy services

2510

Since the NRC's primary regulatory focus appears to be based on the unsubstantiated assumption that misadministrations, particularly those involving diagnostic radiopharmaceuticals, pose a serious threat to the public health and safety. We strongly urge the NRC to pursue a comprehensive study by a reputable scientific panel, such as the National Academy of Sciences or the NCRP, to assess the radiobiological effects of misadministrations from Nuclear Medicine diagnostic and therapeutic studies. We firmly believe that the results of such a study will demonstrate that the NRC's efforts to impose more and more stringent regulations are unnecessary and not cost-effective in relation to the extremely low health risks of these studies.

In closing, we strongly urge the NRC to adopt the ACNP/SNM Petition for Rulemaking as expeditiously as possible.

Sincerely,

Mick Campolongo, R.Ph.

Manager, Syncor International Corporation

Carla C Pemberton

Carla C. Pemberton, R.Ph.

A. Todd Cole, R.Ph.

a zodd Col